Major trial tests new pill to halt worsening of debilitating MS
NCT ID NCT07067463
Summary
This study aims to see if a new oral medication called orelabrutinib can slow the worsening of disability in people with primary progressive multiple sclerosis (PPMS). About 705 participants will be randomly assigned to receive either the study drug or a placebo for up to 5 years. The main goal is to measure if the drug delays the time it takes for walking, hand function, or overall disability to get significantly worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurology Associates, PA
RECRUITINGMaitland, Florida, 32751, United States
-
Premier Neurology
RECRUITINGGreenville, South Carolina, 29605, United States
Conditions
Explore the condition pages connected to this study.